AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 61 min read$KAPA

Kairos Pharma, Ltd. (KAPA) Reports Statistically Significant Phase 2 PFS Benefit

Kairos Pharma reported interim Phase 2 results showing ENV-105 plus apalutamide had a median PFS of 17.7 months vs 2 months with apalutamide alone. The company modified the trial to include earlier-stage patients using enzalutamide.

Original reporting
tradingview.com
Published Oct 6, 2026, 11:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 11:39 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Kairos Pharma, Ltd. (KAPA) Reports Statistically Significant Phase 2 PFS Benefit — source image
Source · tradingview.com
Decision brief

The 30-second read

$KAPABullishMed
01

Why it matters

The statistically significant PFS improvement could re‑price the company's pipeline and attract partnership interest.

02

Market read

First‑report clinical data likely to move KAPA stock and influence related biotech valuations.

03

What to watch

Trial redesign to earlier‑stage patients may affect comparability of results.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Kairos Pharma announced interim Phase 2 results for its candidate ENV-105 in combination with apalutamide.

Company-level read

Ticker impact

$KAPABullishHigh confidence
Context

Interim Phase 2 data shows ENV-105 plus apalutamide improves median PFS to 17.7 months vs 2 months alone.

Expected impact

potential upside as market prices in the strong PFS result

Evidence & confidence

Phase 2 interim data is a material, first‑report clinical milestone that can shift valuation.

Market effects

Sector

May boost sentiment for prostate‑cancer biotech peers.

Regional

Limited to US biotech sector.

Global

Modest, confined to oncology drug development space.

Counterpoint

What could challenge this read

Data is interim; later readouts could temper expectations.

Key entities

  • company
    Kairos Pharma, Ltd.

    Biotech firm developing ENV-105 for prostate cancer.

Read at source← All news

StoryKairos Pharma reports interim Phase 2 progression‑free survival benefit for ENV‑105 plus apalutamide

Related articles

OCT 6
$KAPAMedAI 9/10

Kairos Pharma reports positive Phase 2 interim PFS data; median PFS 17.7 vs 2 months

Kairos Pharma reported Phase 2 interim data showing median progression-free survival of 17.7 months for ENV-105 plus apalutamide vs 2 months for apalutamide alone (P=0.0008). The trial protocol was modified to enroll patients earlier and expand the eligible population, with trial completion targeted for Q4 2027. ENV-105 is a CD105 antibody aimed at reversing drug resistance.

tradingview.com1 min
OCT 6
$KAPAMedAI 9/10

Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer

Kairos Pharma, LTD. (KAPA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer LOS ANGELES — October 6, 2026 — Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company addressin

SEC EDGAR 8-K2 min
OCT 9
$LEVIMed

BNP Paribas Exane raises Levi Strauss price target to $35

BNP Paribas Exane raised its price target for Levi Strauss (LEVI) to $35, citing strong revenue growth and margins. The company reported Q3 revenue of $1.6B, up 4.3%, and EPS of $0.48, beating some estimates. Analysts note challenges in direct-to-consumer sales but see long-term growth potential. Other firms adjusted targets, ranging from $22 to $27.

investing.com2 min